<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:29:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10249509" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10249509</identifier>
        <datestamp>2023-06-09</datestamp>
        <setSpec>crc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Res Commun</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Res Commun</journal-id>
              <journal-title-group>
                <journal-title>Cancer Research Communications</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2767-9764</issn>
              <publisher>
                <publisher-name>American Association for Cancer Research</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10249509</article-id>
              <article-id pub-id-type="pmcid">PMC10249509</article-id>
              <article-id pub-id-type="pmc-uid">10249509</article-id>
              <article-id pub-id-type="pmid">37377613</article-id>
              <article-id pub-id-type="publisher-id">CRC-23-0060</article-id>
              <article-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0060</article-id>
              <article-version id="ver1" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Genitourinary Cancers</subject>
                  <subj-group subj-group-type="category">
                    <subject>Renal Cancer</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Immunotherapy</subject>
                  <subj-group subj-group-type="category">
                    <subject>Checkpoint Blockade</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Drug Targets</subject>
                  <subj-group subj-group-type="category">
                    <subject>Cell Surface Receptor Drug Targets</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Clinical Trial Results</subject>
                  <subj-group subj-group-type="category">
                    <subject>Phase I clinical trials</subject>
                    <subject>Phase II clinical trials</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma</article-title>
                <alt-title alt-title-type="short">Pembrolizumab and Cabozantinib in Metastatic RCC</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7285-867X</contrib-id>
                  <name>
                    <surname>Kessler</surname>
                    <given-names>Elizabeth R.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-9028-8098</contrib-id>
                  <name>
                    <surname>Callihan</surname>
                    <given-names>Eryn</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5937-7916</contrib-id>
                  <name>
                    <surname>Hu</surname>
                    <given-names>Junxiao</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8430-1040</contrib-id>
                  <name>
                    <surname>Eule</surname>
                    <given-names>Corbin</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-4293-4568</contrib-id>
                  <name>
                    <surname>Srivastava</surname>
                    <given-names>Geetika</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-0352-0585</contrib-id>
                  <name>
                    <surname>Kemme</surname>
                    <given-names>Douglas J.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8474-3669</contrib-id>
                  <name>
                    <surname>Iruku</surname>
                    <given-names>Praveena</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0004-3113-5052</contrib-id>
                  <name>
                    <surname>Rana</surname>
                    <given-names>Vishal</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-6860-5039</contrib-id>
                  <name>
                    <surname>Moore</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7766-6295</contrib-id>
                  <name>
                    <surname>Schuster</surname>
                    <given-names>Steven R.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9588-0730</contrib-id>
                  <name>
                    <surname>Amirault</surname>
                    <given-names>Mali</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6145-9040</contrib-id>
                  <name>
                    <surname>Flaig</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5629-3402</contrib-id>
                  <name>
                    <surname>Lam</surname>
                    <given-names>Elaine T.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.</aff>
              <aff id="aff2"><label>2</label>University of Colorado Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, Colorado.</aff>
              <aff id="aff3"><label>3</label>UCHealth Cancer Care and Hematology Clinic, Memorial Hospital Central, Colorado Springs, Colorado.</aff>
              <aff id="aff4"><label>4</label>UCHealth Cancer Center Harmony Campus, Poudre Valley Hospital, Fort Collins, Colorado.</aff>
              <aff id="aff5"><label>5</label>UCHealth Lone Tree Medical Center, Lone Tree, Colorado.</aff>
              <author-notes>
                <fn id="afn1">
                  <p>Current address for P. Iruku: Cone Health Cancer Center, Greensboro, North Carolina; and current address for M. Amirault, Massachusetts General Hospital, Boston, Massachusetts.</p>
                </fn>
                <fn id="afn2">
                  <p><bold>Prior Presentations:</bold> The clinical trial results were presented in part at the American Society of Clinical Oncology GU Symposium 2019, San Francisco, CA, February 14–16, 2019, and at the American Society of Clinical Oncology Annual Meeting 2021, Virtual, June 4–8, 2021.</p>
                </fn>
                <corresp id="cor1"><bold>Corresponding Author:</bold> Elaine T. Lam, University of Colorado Cancer Center, 1665 Aurora Ct., Mailstop F704, Aurora, CO 80045. Phone: 720-848-0170; E-mail: <email>elaine.lam@cuanschutz.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection" iso-8601-date="2023-06-08">
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2023-06-08">
                <day>08</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <volume>3</volume>
              <issue>6</issue>
              <fpage>1004</fpage>
              <lpage>1012</lpage>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>18</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 The Authors; Published by the American Association for Cancer Research</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Copyright held by the owner/author(s).</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="crc-23-0060.pdf"/>
              <abstract>
                <sec>
                  <title>Purpose:</title>
                  <p>Immune checkpoint inhibitor and VEGFR inhibitor combinations are effective treatments for patients with metastatic renal cell carcinoma (mRCC). This phase I/II clinical trial evaluated the safety and efficacy of pembrolizumab and cabozantinib in patients with mRCC.</p>
                </sec>
                <sec>
                  <title>Experimental Design:</title>
                  <p>Eligible patients had mRCC with clear-cell or non-clear cell histology, adequate organ function, Eastern Cooperative Oncology Group 0–1 performance status, and no prior exposure to pembrolizumab or cabozantinib. The primary endpoint was objective response rate (ORR) at the recommended phase II dose (RP2D). Secondary endpoints included safety, disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>Forty-five patients were enrolled. A total of 40 patients were treated at the RP2D of pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily, 38 of which were evaluable for response. The ORR was 65.8% [95% confidence interval (CI), 49.9–78.8] for all evaluable patients [78.6% as first-line therapy, 58.3% as second-line therapy]. The DCR was 97.4% (95% CI, 86.5–99.9). Median DoR was 8.3 months (interquartile range, 4.6–15.1). At a median follow-up of 23.54 months, the median PFS was 10.45 months (95% CI, 6.25–14.63) and median OS was 30.81 months (95% CI, 24.2–not reached). The most common grade 1 and/or 2 treatment-related adverse events (TRAE) were diarrhea, anorexia, dysgeusia, weight loss, and nausea. The most common grade 3 and/or 4 TRAEs were hypertension, hypophosphatemia, alanine transaminase elevation, diarrhea, and fatigue. There was one grade 5 TRAE of reversible posterior encephalopathy syndrome related to cabozantinib.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>Pembrolizumab and cabozantinib treatment in patients with mRCC demonstrated encouraging preliminary efficacy and a manageable toxicity profile comparable with other available checkpoint inhibitor-tyrosine kinase inhibitor combinations.</p>
                </sec>
                <sec>
                  <title>Trial Registration:</title>
                  <p>ClinicalTrials.gov Identifier: NCT03149822 <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03149822" ext-link-type="uri" xlink:show="new">https://clinicaltrials.gov/ct2/show/NCT03149822</ext-link></p>
                </sec>
                <sec>
                  <title>Significance:</title>
                  <p>This study evaluated the safety and effectiveness of the combination of pembrolizumab and cabozantinib in patients with mRCC. The safety profile was manageable. The combination showed promising activity with an objective response rate of 65.8%, median PFS of 10.45 months, and median OS of 30.81 months.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id>http://dx.doi.org/10.13039/100000054</institution-id>
                      <institution>HHS | NIH | National Cancer Institute (NCI)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30CA046934</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kessler</surname>
                      <given-names>Elizabeth R.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Callihan</surname>
                      <given-names>Eryn</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Hu</surname>
                      <given-names>Junxiao</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Eule</surname>
                      <given-names>Corbin J.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Flaig</surname>
                      <given-names>Thomas W.</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Lam</surname>
                      <given-names>Elaine T.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id>http://dx.doi.org/10.13039/100000054</institution-id>
                      <institution>HHS | NIH | National Cancer Institute (NCI)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5K12CA086913</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Lam</surname>
                      <given-names>Elaine T.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>crossmark</meta-name>
                  <meta-value>true</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Kidney cancer is an important cancer worldwide with an estimated 431,000 new cases globally and 81,800 new cases in the United States with a 5-year survival of 13% for stage IV disease (<xref rid="bib1" ref-type="bibr">1, 2</xref>). The development of multiple VEGFR tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (CPI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC; refs. <xref rid="bib3" ref-type="bibr">3–9</xref>). Sunitinib, a TKI-targeting VEGFR and platelet-derived growth factor receptor, was approved in 2006 and established a new first-line (1 L) standard of care for mRCC (<xref rid="bib5" ref-type="bibr">5, 6</xref>). The approval of nivolumab, a mAb against the programmed cell death protein 1 (PD-1) cell surface membrane receptor, as a second- or subsequent-line (2 L) treatment in 2015 heralded the CPI era for mRCC (<xref rid="bib7" ref-type="bibr">7</xref>). Multiple combination therapies are now approved in the front-line setting including nivolumab and ipilimumab, pembrolizumab and axitinib, avelumab and axitinib, nivolumab and cabozantinib, and pembrolizumab and lenvatinib (<xref rid="bib8" ref-type="bibr">8–12</xref>).</p>
              <p>Pembrolizumab, a potent and highly selective humanized monoclonal anti-PD-1 antibody, has demonstrated survival benefit in combination with the VEGFR TKIs axitinib and lenvatinib in the 1 L setting (<xref rid="bib9" ref-type="bibr">9, 12</xref>). Cabozantinib is an oral, small-molecule TKI that targets MET, VEGFR2/KDR, RET, KIT, FLT3, and AXL that has activity as monotherapy in the 1 L and 2 L settings and in combination with nivolumab in the 1 L setting (<xref rid="bib7" ref-type="bibr">7, 11, 13</xref>). Preclinical studies have shown multiple mechanisms of synergy between VEGFR and PD-1 inhibition (<xref rid="bib14" ref-type="bibr">14–18</xref>).</p>
              <p>In this phase I/II, open-label study, we evaluated the safety, tolerability, and antitumor activity of pembrolizumab and cabozantinib in patients with mRCC.</p>
            </sec>
            <sec sec-type="methods" id="sec2">
              <title>Materials and Methods</title>
              <sec id="sec2-1">
                <title>Patient Eligibility</title>
                <p>Eligible patients had histologically confirmed, locally advanced, recurrent, or mRCC. Patients with clear-cell RCC (ccRCC) or non-clear cell RCC (nccRCC) were included. Key inclusion criteria were Eastern Cooperative Oncology Group 0–1 performance status, adequate organ function, and resolution of prior treatment-related toxicities to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 1 or less. Key exclusion criteria were prior treatment with pembrolizumab or cabozantinib; prior anticancer mAb therapy within 4 weeks and prior anticancer targeted small-molecule therapy within 2 weeks of day 1 of study treatment; active autoimmune disease requiring systemic treatment in the past 2 years, diagnosis of immunodeficiency, current systemic steroid therapy equivalent to ≥10 mg/day of prednisone; history of osteonecrosis of the jaw, reversible posterior leukoencephalopathy syndrome (RPLS), pneumonitis, or wound dehiscence within 6 months of study; or uncontrolled or significant intercurrent cardiovascular, gastrointestinal, or pulmonary disorders. There was no requirement or limit on the number of prior anticancer therapies.</p>
              </sec>
              <sec id="sec2-2">
                <title>Study Design and Treatment</title>
                <p>Phase I dose escalation was done using a standard 3 + 3 design. Phase II dose expansion was done using a Simon two-stage design (<xref rid="bib19" ref-type="bibr">19–20</xref>). Pembrolizumab was administered at a fixed dose of 200 mg by intravenous infusion every 3 weeks each 21-day cycle for up to 35 cycles in the first course. Patients could resume a second course of up to an additional 17 cycles of pembrolizumab treatment if they had disease progression after completing the first course. Cabozantinib was taken orally once daily on a continuous basis at a dose of 40 mg orally once daily or 60 mg orally once daily in phase I, and at the recommended phase II dose (RP2D) in phase II. Cabozantinib dose reductions and interruptions were allowed for management of adverse events (AE). Pembrolizumab was held if needed for AEs. Patients continued treatment in the absence of unacceptable toxicity or clinically compelling disease progression. Treatment beyond progression was allowed if the patient met prespecified criteria and was continuing to derive clinical benefit.</p>
                <p>The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. The protocol was approved by the Institutional Review Board and all patients provided written informed consent prior to study procedures.</p>
              </sec>
              <sec id="sec2-3">
                <title>Study Endpoints</title>
                <p>The primary endpoint of the overall study was objective response rate (ORR) in patients treated at the RP2D of pembrolizumab and cabozantinib. Secondary endpoints included dose-limiting toxicities (DLT), MTD, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of treatment, time to response, and duration of response (DoR). Exploratory endpoints included PD-L1 status of archival tumor samples and serum bone turnover markers in patients with bone metastases.</p>
              </sec>
              <sec id="sec2-4">
                <title>Antitumor Activity Assessments</title>
                <p>Tumor assessments were performed at baseline and every 9 weeks on study. Tumor responses were evaluated based on investigator assessment per RECIST 1.1 (<xref rid="bib21" ref-type="bibr">21</xref>). ORR was defined as the sum of complete response (CR) and partial response (PR). DCR was defined as the sum of CR + PR + stable disease (SD). Patients with missing or no response assessments were classified as not evaluable. PFS was defined as the time from study treatment initiation to the first occurrence of documented disease progression or death from any cause during the study. OS was defined as the time from study treatment initiation to death from any cause.</p>
              </sec>
              <sec id="sec2-5">
                <title>Safety Assessments</title>
                <p>DLT was defined as any treatment-related AE (TRAE) grade 3 or higher that occurred during the 21-day DLT assessment window. Any dose-escalation patient who did not complete the DLT period for any reason other than a DLT was replaced by an additional patient at that same dose level. DLT-evaluable patients were required to have received the planned cycle 2 dose of pembrolizumab within 7 days of the planned administration date and to have taken 75% or more of the planned doses of cabozantinib in cycle 1. The MTD was defined as the highest dose level with no more than 1 DLT reported in 6 DLT-evaluable subjects. The RP2D of cabozantinib was selected on the basis of the clinical data, not exceeding the MTD. If &lt;2/6 subjects experience a DLT at 60 mg daily during dose escalation, then 60 mg daily would be considered the RP2D.</p>
                <p>AEs were recorded throughout the study and during the follow-up period and graded according to NCI CTCAE Version 4.0 (<xref rid="bib22" ref-type="bibr">22</xref>). AEs were characterized in terms regarding seriousness, causality, toxicity grading, and action taken regarding trial treatment. Serious AEs (SAE) were defined as any AE that was life threatening; resulted in death, persistent or significant disability/incapacity, hospitalization, or prolongation of an existing inpatient hospitalization; or other important medical events.</p>
              </sec>
              <sec id="sec2-6">
                <title>Exploratory Assessments</title>
                <p>PD-L1 testing was performed on archival tumor tissues by Discovery Life Sciences (formerly QualTek Molecular Laboratories) using a previously validated IHC assay for PD-L1 using the Merck &amp; Co., Inc proprietary mouse mAb clone 22C3 for the testing of formalin-fixed, paraffin-embedded tissues (<xref rid="bib23" ref-type="bibr">23</xref>). Interpretation of PD-L1 (22C3) reactivity was performed by evaluating the percentage of tumor, including tumor-infiltrating mononuclear inflammatory cells, which demonstrates membrane staining low (1+), moderate (2+), and high (3+) intensities. The PD-L1 modified percent score (MPS) represents the sum of the percentage of tumor that has low (1+), moderate (2+), and high (3+) intensity. MPS ≥ 1 is considered positive. Bone turnover markers including β C-terminal telopeptide (β-CTX), bone-specific alkaline phosphatase (BS-ALP), and procollagen type 1 amino-terminal propeptide (P1NP) were collected at baseline and on treatment in patients with bone metastases.</p>
              </sec>
              <sec id="sec2-7">
                <title>Statistical Analysis</title>
                <p>The planned enrollment was estimated to be 6–9 evaluable patients in phase I and 20–38 evaluable patients in phase II. For the primary endpoint of ORR, a Simon two-stage design was used to test the null hypothesis that ORR ≤ 0.20 versus the alternative that ORR ≥ 0.50. After enrollment of 20 evaluable patients in the first stage, the trial would be terminated if 2 or fewer patients respond. If the trial continues to the second stage, a total of 38 patients would be studied. Patients from the phase I dose escalation who were treated at the RP2D were included in the efficacy assessments in Simon stage 1 of the phase II dose expansion.</p>
                <p>The ORR, along with a 95% confidence interval (CI), was estimated. The PFS and OS survival curves and medians were estimated using the Kaplan–Meier method and reported with the corresponding two-sided 95% Brookmeyer–Crowley CI, from the on-treatment date to progressive disease (PD), death, or data cut-off date. All statistical analyses were performed by an independent statistician to ensure unbiased data review and conducted on R version 4.1.0, R Core Team (2021).</p>
              </sec>
              <sec sec-type="data-availability" id="sec2-8">
                <title>Data Availability Statement</title>
                <p>Source data generated in this study are not publicly available due to compromise of patient privacy. Derived data supporting the findings of this study may be available from the corresponding author upon request.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <sec id="sec3-1">
                <title>Patients</title>
                <p>Between October 2017 and August 2020, 45 patients were enrolled (8 patients in phase I and 37 patients in phase II) across five sites within the University of Colorado/UCHealth system. A total of 40 patients were treated at the RP2D and were evaluable for PFS and OS, and 38 patients were evaluable for response (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Baseline characteristics for all patients are listed in <xref rid="tbl1" ref-type="table">Table 1</xref>. Thirty-eight patients (84%) had ccRCC and 7 patients (16%) had nccRCC (5 chromophobe, 2 papillary). Four patients (8.9%) had sarcomatoid differentiation. Thirty patients (67%) had prior exposure to CPI and/or VEGFR therapy. At the time of data analysis, 3 patients remained on study treatment and 42 patients discontinued treatment [26 (62%) due to progression, 14 (33%) due to AEs, and 2 (5%) due to other reasons].</p>
                <fig position="float" id="fig1">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>CONSORT diagram and patient disposition. DLT, dose-limiting toxicity; RP2D, recommended phase II dose; P, pembrolizumab; C, cabozantinib.</p>
                  </caption>
                  <graphic xlink:href="crc-23-0060_fig1" position="float"/>
                </fig>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Baseline characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">N</italic> = 45 (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Median age, years (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">61.0 (54.0–69.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sex, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Female</td>
                        <td align="left" rowspan="1" colspan="1">12 (26.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Male</td>
                        <td align="left" rowspan="1" colspan="1">33 (73.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Race, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> White</td>
                        <td align="left" rowspan="1" colspan="1">40 (88.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Black</td>
                        <td align="left" rowspan="1" colspan="1">3 (6.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Asian</td>
                        <td align="left" rowspan="1" colspan="1">2 (4.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Ethnicity, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">2 (4.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">38 (84.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Unknown/Not reported</td>
                        <td align="left" rowspan="1" colspan="1">5 (11.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ECOG, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 0</td>
                        <td align="left" rowspan="1" colspan="1">9 (20.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 1</td>
                        <td align="left" rowspan="1" colspan="1">36 (80.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IMDC risk group, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Favorable</td>
                        <td align="left" rowspan="1" colspan="1">6 (13.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Intermediate</td>
                        <td align="left" rowspan="1" colspan="1">32 (71.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Poor</td>
                        <td align="left" rowspan="1" colspan="1">7 (15.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior nephrectomy, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Yes</td>
                        <td align="left" rowspan="1" colspan="1">39 (86.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> No</td>
                        <td align="left" rowspan="1" colspan="1">6 (13.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Histology, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Clear cell</td>
                        <td align="left" rowspan="1" colspan="1">38 (84.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-clear cell</td>
                        <td align="left" rowspan="1" colspan="1">7 (15.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Chromophobe</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Papillary</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sites of metastases, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Bone</td>
                        <td align="left" rowspan="1" colspan="1">26 (57.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Lung</td>
                        <td align="left" rowspan="1" colspan="1">33 (73.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Lymph node</td>
                        <td align="left" rowspan="1" colspan="1">28 (62.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Liver</td>
                        <td align="left" rowspan="1" colspan="1">11 (24.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Pancreas</td>
                        <td align="left" rowspan="1" colspan="1">4 (8.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Other</td>
                        <td align="left" rowspan="1" colspan="1">15 (33.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Brain</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Line of therapy on study, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">2.0 (1.0 to 3.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior therapy, no. (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> VEGFR inhibitor only</td>
                        <td align="left" rowspan="1" colspan="1">10 (22)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Checkpoint inhibitor only</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Both VEGFRi and CPI</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Neither VEGFRi nor CPI</td>
                        <td align="left" rowspan="1" colspan="1">15 (33)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: CPI, checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic RCC Database Consortium; IQR, interquartile range; VEGFRi, vascular endothelial growth factor receptor inhibitor.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec3-2">
                <title>MTD and DLT Evaluation</title>
                <p>Eight patients were enrolled in phase I [5 patients in the first cohort of pembrolizumab 200 mg and cabozantinib 40 mg (2 were not evaluable for DLT due to missing ≥25% of the planned cabozantinib doses in cycle 1, not related to TRAE) and 3 patients in the second cohort of pembrolizumab 200 mg and cabozantinib 60 mg]. There were no DLTs observed. The MTD and RP2D were determined to be pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally daily.</p>
              </sec>
              <sec id="sec3-3">
                <title>Safety</title>
                <p>The most common TRAEs in all 45 patients are reported in <xref rid="tbl2" ref-type="table">Table 2</xref>. TRAEs occurred in 44 patients (98%). The five most common grade 1 and 2 AEs were diarrhea (71%), anorexia (62%), dysgeusia (62%), weight loss (62%), and nausea (60%). The most common grade 3 and higher AEs include hypertension (20%), hypophosphatemia (18%), alanine transaminase elevation (11%), diarrhea (9%), and fatigue (7%). Thirty-three patients (73%) experienced a grade 3 AE and there were no grade 4-related AEs. Thirteen patients experienced SAEs, 8 of which were related to treatment: grade 3 transaminitis and hypoglycemia attributed to the combination; grade 3 pancreatitis, nephritis, and pneumonitis attributed to pembrolizumab; and grade 3 pulmonary embolus, confusion due to RPLS, and stroke attributed to cabozantinib. There was one death in the patient with RPLS which was attributed to cabozantinib. TRAEs leading to discontinuation of study treatment occurred in 14 patients (33%): immune-mediated pancreatitis (2), immune-mediated hepatitis (2), intolerable diarrhea (2), elevated liver function tests (LFTs) (2), immune-mediated myocarditis (1), immune-mediated nephritis (1), immune-mediated rash (1), RPLS (1), venous thromboembolism and renal infarcts (1), osteonecrosis of the jaw (1). Twenty-eight of 40 patients (70%) treated at the RP2D required dose reduction of cabozantinib at a median of 4 cycles (range, 1–38).</p>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>TRAEs in ≥10% of patients and all grade ≥3</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" colspan="2" rowspan="1">(<italic toggle="yes">N</italic> = 45) no. (%)</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Adverse event</th>
                        <th align="left" rowspan="1" colspan="1">Grade 1/2</th>
                        <th align="left" rowspan="1" colspan="1">Grade ≥3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Any AE</td>
                        <td align="left" rowspan="1" colspan="1">44 (98)</td>
                        <td align="left" rowspan="1" colspan="1">33 (73)</td>
                      </tr>
                      <tr>
                        <td colspan="3" align="left" rowspan="1">
                          <bold>Clinical AE</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="left" rowspan="1" colspan="1">32 (71)</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anorexia</td>
                        <td align="left" rowspan="1" colspan="1">28 (62)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dysgeusia</td>
                        <td align="left" rowspan="1" colspan="1">28 (62)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Weight loss</td>
                        <td align="left" rowspan="1" colspan="1">28 (62)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nausea</td>
                        <td align="left" rowspan="1" colspan="1">27 (60)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Palmar-plantar erythrodysesthesia</td>
                        <td align="left" rowspan="1" colspan="1">25 (56)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fatigue</td>
                        <td align="left" rowspan="1" colspan="1">22 (49)</td>
                        <td align="left" rowspan="1" colspan="1">3 (7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mucosal inflammation</td>
                        <td align="left" rowspan="1" colspan="1">19 (42)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">17 (38)</td>
                        <td align="left" rowspan="1" colspan="1">9 (20)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Rash</td>
                        <td align="left" rowspan="1" colspan="1">17 (38)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hair color changes</td>
                        <td align="left" rowspan="1" colspan="1">17 (38)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Vomiting</td>
                        <td align="left" rowspan="1" colspan="1">16 (36)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Abdominal pain</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Arthralgia</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dizziness</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gastroesophageal reflux</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Rhinorrhea</td>
                        <td align="left" rowspan="1" colspan="1">11 (24)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dry skin</td>
                        <td align="left" rowspan="1" colspan="1">10 (22)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hoarseness</td>
                        <td align="left" rowspan="1" colspan="1">10 (22)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pruritus</td>
                        <td align="left" rowspan="1" colspan="1">9 (20)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sore throat</td>
                        <td align="left" rowspan="1" colspan="1">9 (20)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Constipation</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Peripheral edema</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nasal congestion</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Headache</td>
                        <td align="left" rowspan="1" colspan="1">7 (16)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dry mouth</td>
                        <td align="left" rowspan="1" colspan="1">7 (16)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Epistaxis</td>
                        <td align="left" rowspan="1" colspan="1">6 (13)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dysphagia</td>
                        <td align="left" rowspan="1" colspan="1">6 (13)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dyspnea</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Generalized muscle weakness</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myalgia</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Dehydration</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Oral pain</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cold intolerance</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Flatulence</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hair loss/thinning</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Muscle cramps</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Thromboembolic event</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Altered mental status</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Palpitations</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">3 (7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pancreatitis</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Pneumonitis</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RPLS</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)<xref rid="tb1fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sepsis</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td colspan="3" align="left" rowspan="1">
                          <bold>Any laboratory AE</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">AST increased</td>
                        <td align="left" rowspan="1" colspan="1">19 (42)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ALT increased</td>
                        <td align="left" rowspan="1" colspan="1">17 (38)</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypothyroidism</td>
                        <td align="left" rowspan="1" colspan="1">19 (42)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypophosphatemia</td>
                        <td align="left" rowspan="1" colspan="1">11 (24)</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Proteinuria</td>
                        <td align="left" rowspan="1" colspan="1">12 (27)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anemia</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypokalemia</td>
                        <td align="left" rowspan="1" colspan="1">8 (18)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Increased blood creatinine</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypomagnesemia</td>
                        <td align="left" rowspan="1" colspan="1">5 (11)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Increased alkaline phosphatase</td>
                        <td align="left" rowspan="1" colspan="1">4 (9)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hyperglycemia</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypocalcemia</td>
                        <td align="left" rowspan="1" colspan="1">2 (4)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; No., number of patients; RPLS, reversible posterior leukoencephalopathy syndrome.</p>
                    </fn>
                    <fn id="tb1fn1">
                      <p><sup>a</sup>Grade 5.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec3-4">
                <title>Efficacy</title>
                <p>Thirty-eight patients were evaluable for tumor response at the RP2D (pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally daily). The ORR was 65.8% (25/38 patients, 95% CI, 49.9–78.8) with 1 CR, 24 PR, 12 SD, 1 PD. The ORR was 78.6% (11/14) in evaluable patients who received study treatment as 1 L therapy and 58.3% (14/24) among patients who received it as second- or subsequent-line therapy. By type or prior therapy, the ORR was 37.5% in patients who had previously received VEGF/R inhibitor only, 62.5% in patients with prior CPI only, 75% in patients who had received both VEGF/R inhibitor and CPI (either in combination or sequentially), and 78.6% in patients who had received no prior therapy (<xref rid="SMT1" ref-type="supplementary-material">Supplementary Table S1</xref>). The ORR was 17% (1/6) in patients without prior nephrectomy and 75% (23/32) in patients with prior nephrectomy. Best response by RECIST in evaluable patients treated at RP2D is presented by histology in <xref rid="tbl3" ref-type="table">Table 3</xref>. With the caveat of small number of patients, there were no objective responses among the 5 evaluable patients treated in dose-escalation cohort of pembrolizumab 200 mg and cabozantinib 40 mg (<xref rid="SMT2" ref-type="supplementary-material">Supplementary Table S2</xref>). One patient with chromophobe RCC treated at this dose level had prolonged disease stability lasting over 3 years. The DCR was 97.4% (95% CI, 86.5–99.9). Median DoR was 8.3 months (IQR, 4.6–15.1). The best percentage change in tumor size from baseline and the time on treatment for all evaluable patients in phase I and phase II parts of the study are presented in <xref rid="fig2" ref-type="fig">Fig. 2A</xref> and <xref rid="fig2" ref-type="fig">B</xref>, respectively. The median duration of treatment was 8.3 months (<italic toggle="yes">n</italic> = 45; IQR, 4.6–15.1), median time to response was 2.2 months (<italic toggle="yes">n</italic> = 25; IQR, 2.0–4.1), and median DoR was 8.3 months (<italic toggle="yes">n</italic> = 25; IQR, 4.0–14.3). Eleven patients (24.4%) were treated beyond progression with a median of 4.9 additional months (range, 1.4–37.8) on treatment.</p>
                <table-wrap position="float" id="tbl3">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Best response by RECIST in evaluable patients treated at RP2D (pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily).</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">ccRCC Patients (<italic toggle="yes">N</italic> = 33)</th>
                        <th align="left" rowspan="1" colspan="1">nccRCC Patients (<italic toggle="yes">N</italic> = 5)</th>
                        <th align="left" rowspan="1" colspan="1">All evaluable patients (<italic toggle="yes">N</italic> = 38)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Objective response rate, no. (%, 95% CI)</td>
                        <td align="left" rowspan="1" colspan="1">22 (66.7%, 49.6–80.2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (60%, 23.1–88.2)</td>
                        <td align="left" rowspan="1" colspan="1">25 (65.8%, 49.9–78.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Best overall response, no. (%)</td>
                        <td colspan="3" align="left" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Complete response</td>
                        <td align="left" rowspan="1" colspan="1">1 (3%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Partial response</td>
                        <td align="left" rowspan="1" colspan="1">21 (63.6%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (60%)</td>
                        <td align="left" rowspan="1" colspan="1">24 (63.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Stable disease</td>
                        <td align="left" rowspan="1" colspan="1">11 (33.3%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">12 (31.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Progressive disease</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Disease control rate, no. (%, 95% CI)</td>
                        <td align="left" rowspan="1" colspan="1">33 (100%, 89.6–100)</td>
                        <td align="left" rowspan="1" colspan="1">4 (80%, 37.6–99)</td>
                        <td align="left" rowspan="1" colspan="1">37 (97.4%, 86.5–99.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Time to response, median (range), months</td>
                        <td align="left" rowspan="1" colspan="1">3.1 (1.9–12.4)</td>
                        <td align="left" rowspan="1" colspan="1">2.1 (2.1–2.1)</td>
                        <td align="left" rowspan="1" colspan="1">2.2 (1.9–12.4)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: ccRCC, clear-cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="fig2">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Clinical activity of pembrolizumab and cabozantinib. <bold>A,</bold> Best percent change from baseline as measured by RECIST 1.1 in all evaluable patients from both phase I and phase II (<italic toggle="yes">N</italic> = 43). <bold>B,</bold> Swimmer plot of time on treatment in months for in all evaluable patients from both phase I and phase II (<italic toggle="yes">N</italic> = 43). ccRCC, clear-cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.</p>
                  </caption>
                  <graphic xlink:href="crc-23-0060_fig2" position="float"/>
                </fig>
                <p>All 40 patients treated at the RP2D were included in the survival analyses. There were 33 PFS events and 16 OS events. The median PFS was 10.45 months (95% CI, 6.25–14.63; <xref rid="fig3" ref-type="fig">Fig. 3A</xref>). At a median follow-up of 23.54 months, the median OS was 30.81 months (95% CI, 24.23–not evaluable; <xref rid="fig3" ref-type="fig">Fig. 3B</xref>). The median PFS and OS for only patients with ccRCC is presented in <xref rid="SMF1" ref-type="supplementary-material">Supplementary Fig. S1</xref>.</p>
                <fig position="float" id="fig3">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Kaplan–Meier curves of PFS (<bold>A</bold>) and OS (<bold>B</bold>) for all patients treated at the RP2D of pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily (<italic toggle="yes">N</italic> = 40). Vertical lines show censored patients.</p>
                  </caption>
                  <graphic xlink:href="crc-23-0060_fig3" position="float"/>
                </fig>
              </sec>
              <sec id="sec3-5">
                <title>Exploratory Studies</title>
                <p>There were 44 samples of archival tissue available for PD-L1 testing, 40 of which (90.9%) were interpretable and four samples which did not have tumor in the specimen. Of the 40 evaluable samples, 32 (80.0%) had PD-L1 tumor MPS ≥ 1. The ORR was 69% in patients with PD-L1–positive samples and 50% in patients with PD-L1–negative samples. The median MPS of patients with an objective response was 2.5 (range, 0–100) as compared with 10 (range, 0–85) in patients without a treatment response. Two patients with PD had MPS of 20 and 70. The patient with CR had MPS 40.</p>
                <p>Twenty-three of 26 patients with bone metastases had bone turnover markers collected at baseline. Very few patients had elevated bone turnover markers at baseline: 1 for beta-cross-linked C-terminal telopeptide (β-CTX; 4.3%), 3 for BS-ALP (13.0%), and 3 for P1NP (13.0%). The ORR in patients with bone metastases was 38.5%. At the time of the first on-treatment scans at 9 weeks, P1NP had decreased in all patients regardless of treatment response. Among patients with PD (2 patients) or a PR (6 patients) who had bone turnover markers collected at baseline and at 9 weeks, change in β-CTX and BS-ALP was concordant with radiographic response in 71.4% and 62.5% patients, respectively.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>We conducted this phase I/II study of pembrolizumab and cabozantinib beginning in 2017, prior to the FDA approvals of combination CPI-TKI therapies including pembrolizumab and axitinib in 2019, and nivolumab and cabozantinib and pembrolizumab and lenvatinib in 2021. In our study, the primary endpoint of ORR for all patients treated at the RP2D was met, with ORR 65.8%. The ORR was 73.3% among 1 L patients and 56% among 2 L patients. These results are better than historical results from cabozantinib alone (33% in 1 L and 21% in 2 L+; refs. <xref rid="bib7" ref-type="bibr">7, 13</xref>) and similar to the reported ORR for 1 L CPI-TKI studies of axitinib and pembrolizumab (59.3%), cabozantinib and nivolumab (55.7%), lenvatinib and pembrolizumab (71%), as well as the 2 L cabozantinib plus atezolizumab study where ORR was 53% and 58% in the in the 40 mg and 60 mg ccRCC groups, respectively (<xref rid="bib9" ref-type="bibr">9, 11, 12, 24</xref>). Compared with other landmark trials, our study had a higher proportion of patients with International Metastatic RCC Database Consortium (IMDC) intermediate risk and a lower proportion of patients with IMDC poor risk. In addition, the CR rate of 2.6% in our study is lower compared with landmark 1 L combination studies. One possible explanation for this is that 63% of all evaluable patients (24/38) in our study had prior CPI and/or VEGFR therapy. The ORR in patients with nccRCC was 50%; however, this group represents a small subset of the overall population, and no conclusion can be drawn. Recent studies in patients with nccRCC have shown activity with pembrolizumab monotherapy (ORR 26.7%), cabozantinib monotherapy (ORR 27%), and cabozantinib plus atezolizumab combination (ORR 31%; refs. <xref rid="bib24" ref-type="bibr">24–26</xref>). While combination CPI-TKI therapy is well established in the 1 L setting, there are very few studies evaluating combination therapy in the 2 L setting. Our study shows preliminary activity of pembrolizumab and cabozantinib in both the 1 L and 2 L settings for mRCC, suggesting that this combination could be efficacious even after prior CPI and VEGFR exposure.</p>
              <p>The safety profile of pembrolizumab plus cabozantinib was manageable and generally consistent with AEs reported with other CPI-TKI combinations. As with the phase I nivolumab and cabozantinib study (<xref rid="bib27" ref-type="bibr">27</xref>), the AEs related to pembrolizumab and cabozantinib were manageable with early recognition and management of immune-mediated and non–immune-mediated AEs and dose reduction of cabozantinib. While the phase III nivolumab plus cabozantinib combination uses a starting cabozantinib dose of 40 mg/day (<xref rid="bib28" ref-type="bibr">28</xref>), in our study, the RP2D of cabozantinib in combination with pembrolizumab is 60 mg/day. However, 70% of patients required dose reduction of cabozantinib. This is higher compared with 60% and 46% of cabozantinib monotherapy patients with dose reductions in the METEOR and CABOSUN studies, respectively (<xref rid="bib7" ref-type="bibr">7, 13</xref>). In general, the incidence of grade 3 or 4 TRAEs with pembrolizumab and cabozantinib in our study was similar to that reported for the cabozantinib plus nivolumab and cabozantinib plus atezolizumab studies (<xref rid="bib24" ref-type="bibr">24, 28</xref>). As with other CPI-TKI combinations, the overlapping toxicities seen with pembrolizumab plus cabozantinib include diarrhea, elevated liver enzymes, and hypothyroidism. There were no new safety signals in terms of general TRAEs and immune-mediated AEs.</p>
              <p>Our exploratory analyses included PD-L1 tumor testing in all patients with archival tissue and bone turnover markers in patients with bone metastases at baseline. In contrast to previously seen responses to pembrolizumab in advanced RCC with positive PD-L1 expression (<xref rid="bib29" ref-type="bibr">29</xref>), there was no correlation between MPS and ORR in our patients. The degree of MPS positivity also did not correspond with degree of response, as has been demonstrated in non–small cell lung cancer (<xref rid="bib30" ref-type="bibr">30</xref>). Bone turnover markers were infrequently elevated in patients with bone metastases, indicating their limited diagnostic utility for bone metastases in RCC (<xref rid="bib31" ref-type="bibr">31</xref>). β-CTX, a marker of bone resorption specific to collagen type 1, most accurately detects PD and PR (<xref rid="bib32" ref-type="bibr">32</xref>). BS-ALP, a product of osteoblasts, and P1NP, a product of proliferating osteoblasts and fibroblasts, are both markers of bone formation (<xref rid="bib32" ref-type="bibr">32</xref>). P1NP activity decreased in all patients, making any correlation to treatment possibly coincidental and uninterpretable.</p>
              <sec id="sec4-1">
                <title>Limitations</title>
                <p>Inherent to small phase I/II studies, the main limitations of this clinical trial include small number of patients, single-arm design with no comparator treatment arm, and absence of randomization. Another limitation is the heterogeneity of the patients included in this study. Because of demonstrated activity of cabozantinib in both ccRCC and nccRCC, we included patients with both histologic subtypes. This may have diluted out the true ORR of this combination in ccRCC tumors alone. However, although numbers of patients with nccRCC were small and no formal conclusions can be made, a response rate of 50% (3/6) gave us insight into potential activity of this CPI-TKI combination in nccRCC. These results are consistent with those of the phase II KEYNOTE-B61 study of 147 untreated patients with metastatic nccRCC which showed promising results of ORR 47.6%, DCR 79.3%, 6-month PFS 72.3%, 6-month OS 87.8% (<xref rid="bib33" ref-type="bibr">33</xref>).</p>
                <p>Our study was initially designed with historical comparisons with single-agent cabozantinib. As cabozantinib monotherapy has approval in both 1 L and ≥2 L settings for mRCC, we also included patients regardless of line of therapy. As ORR is expected to be highest with 1 L and lower with 2 L therapies, combining these cohorts could have overestimated the response in the 2 L setting and underestimated the response in the 1 L setting. What we observed was ORR of 65.8% in all response-evaluable patients, ORR 73.3% (11/15 patients) in 1 L and ORR 56% (14/25 patients) in the 2 L setting, which is similar to the reported ORR with other combinations in 1 L or 2 L settings, and higher when compared with cabozantinib alone in these settings.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec5">
              <title>Conclusions</title>
              <p>The combination of pembrolizumab and cabozantinib treatment in patients with mRCC demonstrated encouraging preliminary efficacy that is comparable with other available CPI-TKI combinations with a manageable toxicity profile. Further prospective evaluation of pembrolizumab and cabozantinib is warranted, especially in the 2 L treatment setting and in patients with nccRCC.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="SMF1" position="float" content-type="local-data">
                <label>Supplementary Figure S1</label>
                <caption>
                  <p>Supplemental Figure S1: Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) for patients with clear cell renal cell carcinoma histology (N=34). Vertical lines show censored patients</p>
                </caption>
                <media xlink:href="crc-23-0060-s01.pptx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="SMT1" position="float" content-type="local-data">
                <label>Supplementary Table S1</label>
                <caption>
                  <p>Best Response by RECIST in Evaluable Patients Treated at RP2D (Pembrolizumab 200 mg IV Q3W and Cabozantinib 60 mg PO QD) by Prior Therapy</p>
                </caption>
                <media xlink:href="crc-23-0060-s02.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="SMT2" position="float" content-type="local-data">
                <label>Supplementary Table S2</label>
                <caption>
                  <p>Best Response by RECIST in Evaluable Patients Treated at the Pembrolizumab 200 mg IV Q3W and Cabozantinib 40 mg PO QD Cohort</p>
                </caption>
                <media xlink:href="crc-23-0060-s03.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>We are grateful to the patients who participated in this study, their caretakers, and families. In addition, we thank the study coordinators, nurses, and pharmacy teams at all the study sites, the University of Colorado Cancer Center Cancer Clinical Trials Office, and Oncology Clinical Research Support Team.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p><bold>Note:</bold> Supplementary data for this article are available at Cancer Research Communications Online (<ext-link xlink:href="https://aacrjournals.org/cancerrescommun/" ext-link-type="uri" xlink:show="new">https://aacrjournals.org/cancerrescommun/</ext-link>).</p>
              </fn>
            </fn-group>
            <sec id="sec6">
              <title>Authors’ Disclosures</title>
              <p>E.R. Kessler reports grants from Merck during the conduct of the study; grants from Bristol Myers Squibb, Seattle Genetics, Eli Lily, and AstraZeneca outside the submitted work. J. Moore reports other from Merck outside the submitted work. T.W. Flaig reports other from MERCK and Exelixis during the conduct of the study; other from Aurora Oncology outside the submitted work; in addition, T.W. Flaig has a patent to 2 patents in early stage bladder detection and treatment issued and licensed. E.T. Lam reports grants and other from Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc.; grants from NCI (HHS – NIH) Cancer Center Support Grant P30CA046934, Colorado Cancer Foundation, and NIH/NCI Paul Calabresi Award for Clinical Oncology Research 5K12CA086913 during the conduct of the study; grants and personal fees from Calithera Biosciences and Exelixis; grants from Advaxis, Amgen, Argos Therapeutics, Arrowhead Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb, Constellation Pharmaceuticals, Decibel Therapeutics, Forma Therapeutics, Peloton Therapeutics, Harpoon Therapeutics, OnQuality Pharmaceuticals, Pfizer, Phosplatin Therapeutics, and Genentech/Roche outside the submitted work. No disclosures were reported by the other authors.</p>
            </sec>
            <sec id="sec7">
              <title>Role of the Funder/Sponsor</title>
              <p>This was an investigator-initiated study coordinated by the University of Colorado Cancer Center (sponsor) and E.T. Lam (principal investigator) who were responsible for administering the study and coordinating the subsites involved in the study. The funder did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation or decision to submit the article. The funder has reviewed and approved of the article for publication.</p>
            </sec>
            <sec id="sec8">
              <title>Authors’ Contributions</title>
              <p><bold>E.R. Kessler:</bold> Conceptualization, data curation, validation, investigation, methodology, writing-original draft, project administration, writing-review and editing. <bold>E. Callihan:</bold> Investigation, writing-review and editing. <bold>J. Hu:</bold> Data curation, software, formal analysis. <bold>C. Eule:</bold> Data curation, investigation, writing-review and editing. <bold>G. Srivastava:</bold> Supervision, investigation, project administration, writing-review and editing. <bold>D.J. Kemme:</bold> Investigation, writing-review and editing. <bold>P. Iruku:</bold> Investigation, writing-review and editing. <bold>V. Rana:</bold> Investigation, writing-review and editing. <bold>J. Moore:</bold> Investigation, writing-review and editing. <bold>S.R. Schuster:</bold> Supervision, investigation, writing-review and editing. <bold>M. Amirault:</bold> Investigation, writing-review and editing. <bold>T.W. Flaig:</bold> Investigation, writing-review and editing. <bold>E.T. Lam:</bold> Conceptualization, resources, data curation, supervision, funding acquisition, validation, investigation, visualization, methodology, writing-original draft, project administration, writing-review and editing.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source><year>2021</year>;<volume>71</volume>:<fpage>209</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Wagle</surname><given-names>NS</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J Clin</source><year>2023</year>;<volume>73</volume>:<fpage>17</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">36633525</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name><surname>Eisen</surname><given-names>T</given-names></string-name>, <string-name><surname>Stadler</surname><given-names>WM</given-names></string-name>, <string-name><surname>Szczylik</surname><given-names>C</given-names></string-name>, <string-name><surname>Oudard</surname><given-names>S</given-names></string-name>, <string-name><surname>Siebels</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title>. <source>N Engl J Med</source><year>2007</year>;<volume>356</volume>:<fpage>125</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">17215530</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name><surname>Eisen</surname><given-names>T</given-names></string-name>, <string-name><surname>Stadler</surname><given-names>WM</given-names></string-name>, <string-name><surname>Szczylik</surname><given-names>C</given-names></string-name>, <string-name><surname>Oudard</surname><given-names>S</given-names></string-name>, <string-name><surname>Staehler</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</article-title>. <source>J Clin Oncol</source><year>2009</year>;<volume>27</volume>:<fpage>3312</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">19451442</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Hutson</surname><given-names>TE</given-names></string-name>, <string-name><surname>Tomczak</surname><given-names>P</given-names></string-name>, <string-name><surname>Michaelson</surname><given-names>MD</given-names></string-name>, <string-name><surname>Bukowski</surname><given-names>RM</given-names></string-name>, <string-name><surname>Rixe</surname><given-names>O</given-names></string-name>, <etal/></person-group>. <article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title>. <source>N Engl J Med</source><year>2007</year>;<volume>356</volume>:<fpage>115</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">17215529</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Hutson</surname><given-names>TE</given-names></string-name>, <string-name><surname>Tomczak</surname><given-names>P</given-names></string-name>, <string-name><surname>Michaelson</surname><given-names>MD</given-names></string-name>, <string-name><surname>Bukowski</surname><given-names>RM</given-names></string-name>, <string-name><surname>Oudard</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</article-title>. <source>J Clin Oncol</source><year>2009</year>;<volume>27</volume>:<fpage>3584</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">19487381</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choueiri</surname><given-names>TK</given-names></string-name>, <string-name><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name><surname>Mainwaring</surname><given-names>PN</given-names></string-name>, <string-name><surname>Rini</surname><given-names>BI</given-names></string-name>, <string-name><surname>Donskov</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Cabozantinib versus everolimus in advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>373</volume>:<fpage>1814</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">26406150</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rini</surname><given-names>BI</given-names></string-name>, <string-name><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name><surname>Tomczak</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaprin</surname><given-names>A</given-names></string-name>, <string-name><surname>Szczylik</surname><given-names>C</given-names></string-name>, <string-name><surname>Hutson</surname><given-names>TE</given-names></string-name>, <etal/></person-group>. <article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</article-title>. <source>Lancet</source><year>2011</year>;<volume>378</volume>:<fpage>1931</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sternberg</surname><given-names>CN</given-names></string-name>, <string-name><surname>Davis</surname><given-names>ID</given-names></string-name>, <string-name><surname>Mardiak</surname><given-names>J</given-names></string-name>, <string-name><surname>Szczylik</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>E</given-names></string-name>, <string-name><surname>Wagstaff</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title>. <source>J Clin Oncol</source><year>2010</year>;<volume>28</volume>:<fpage>1061</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">20100962</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Penkov</surname><given-names>K</given-names></string-name>, <string-name><surname>Haanen</surname><given-names>J</given-names></string-name>, <string-name><surname>Rini</surname><given-names>B</given-names></string-name>, <string-name><surname>Albiges</surname><given-names>L</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>MT</given-names></string-name>, <etal/></person-group>. <article-title>Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source><year>2019</year>;<volume>380</volume>:<fpage>1103</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">30779531</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choueiri</surname><given-names>TK</given-names></string-name>, <string-name><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name><surname>Burotto</surname><given-names>M</given-names></string-name>, <string-name><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name><surname>Bourlon</surname><given-names>MT</given-names></string-name>, <string-name><surname>Zurawski</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source><year>2021</year>;<volume>384</volume>:<fpage>829</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">33657295</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Motzer</surname><given-names>R</given-names></string-name>, <string-name><surname>Alekseev</surname><given-names>B</given-names></string-name>, <string-name><surname>Rha</surname><given-names>S-Y</given-names></string-name>, <string-name><surname>Porta</surname><given-names>C</given-names></string-name>, <string-name><surname>Eto</surname><given-names>M</given-names></string-name>, <string-name><surname>Powles</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma</article-title>. <source>N Engl J Med</source><year>2021</year>;<volume>384</volume>:<fpage>1289</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">33616314</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choueiri</surname><given-names>TK</given-names></string-name>, <string-name><surname>Halabi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sanford</surname><given-names>BL</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>O</given-names></string-name>, <string-name><surname>Michaelson</surname><given-names>MD</given-names></string-name>, <string-name><surname>Walsh</surname><given-names>MK</given-names></string-name>, <etal/></person-group>. <article-title>Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial</article-title>. <source>J Clin Oncol</source><year>2017</year>;<volume>35</volume>:<fpage>591</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28199818</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gunturi</surname><given-names>A</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>DF</given-names></string-name></person-group>. <article-title>Potential of new therapies like anti-PD1 in kidney cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2014</year>;<volume>15</volume>:<fpage>137</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">24504486</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ko</surname><given-names>JS</given-names></string-name>, <string-name><surname>Zea</surname><given-names>AH</given-names></string-name>, <string-name><surname>Rini</surname><given-names>BI</given-names></string-name>, <string-name><surname>Ireland</surname><given-names>JL</given-names></string-name>, <string-name><surname>Elson</surname><given-names>P</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients</article-title>. <source>Clin Cancer Res</source><year>2009</year>;<volume>15</volume>:<fpage>2148</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">19276286</pub-id></mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tartour</surname><given-names>E</given-names></string-name>, <string-name><surname>Pere</surname><given-names>H</given-names></string-name>, <string-name><surname>Maillere</surname><given-names>B</given-names></string-name>, <string-name><surname>Terme</surname><given-names>M</given-names></string-name>, <string-name><surname>Merillon</surname><given-names>N</given-names></string-name>, <string-name><surname>Taieb</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy</article-title>. <source>Cancer Metastasis Rev</source><year>2011</year>;<volume>30</volume>:<fpage>83</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">21249423</pub-id></mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Terme</surname><given-names>M</given-names></string-name>, <string-name><surname>Colussi</surname><given-names>O</given-names></string-name>, <string-name><surname>Marcheteau</surname><given-names>E</given-names></string-name>, <string-name><surname>Tanchot</surname><given-names>C</given-names></string-name>, <string-name><surname>Tartour</surname><given-names>E</given-names></string-name>, <string-name><surname>Taieb</surname><given-names>J</given-names></string-name></person-group>. <article-title>Modulation of immunity by antiangiogenic molecules in cancer</article-title>. <source>Clin Dev Immunol</source><year>2012</year>;<volume>2012</volume>:<fpage>492920</fpage>.<pub-id pub-id-type="pmid">23320019</pub-id></mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Voron</surname><given-names>T</given-names></string-name>, <string-name><surname>Colussi</surname><given-names>O</given-names></string-name>, <string-name><surname>Marcheteau</surname><given-names>E</given-names></string-name>, <string-name><surname>Pernot</surname><given-names>S</given-names></string-name>, <string-name><surname>Nizard</surname><given-names>M</given-names></string-name>, <string-name><surname>Pointet</surname><given-names>A-L</given-names></string-name>, <etal/></person-group>. <article-title>VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors</article-title>. <source>J Exp Med</source><year>2015</year>;<volume>212</volume>:<fpage>139</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">25601652</pub-id></mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simon</surname><given-names>R</given-names></string-name></person-group>. <article-title>Optimal two-stage designs for phase II clinical trials</article-title>. <source>Control Clin Trials</source><year>1989</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">2702835</pub-id></mixed-citation>
              </ref>
              <ref id="bib20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname><given-names>S-H</given-names></string-name>, <string-name><surname>Lee</surname><given-names>T</given-names></string-name>, <string-name><surname>Kim</surname><given-names>K</given-names></string-name>, <string-name><surname>George</surname><given-names>SL</given-names></string-name></person-group>. <article-title>Admissible two-stage designs for phase II cancer clinical trials</article-title>. <source>Stat Med</source><year>2004</year>;<volume>23</volume>:<fpage>561</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">14755389</pub-id></mixed-citation>
              </ref>
              <ref id="bib21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>J</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>LH</given-names></string-name>, <string-name><surname>Sargent</surname><given-names>D</given-names></string-name>, <string-name><surname>Ford</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source><year>2009</year>;<volume>45</volume>:<fpage>228</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="bib22">
                <label>22.</label>
                <mixed-citation publication-type="url"><collab>NCI</collab>. <article-title>Common terminology criteria for adverse events (CTCAE), version 4.0</article-title>. Available from: <ext-link xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm" ext-link-type="uri" xlink:show="new">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</ext-link>; <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="bib23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dolled-Filhart</surname><given-names>M</given-names></string-name>, <string-name><surname>Locke</surname><given-names>D</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>T</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>F</given-names></string-name>, <string-name><surname>Yearley</surname><given-names>JH</given-names></string-name>, <string-name><surname>Frisman</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue</article-title>. <source>Arch Pathol Lab Med</source><year>2016</year>;<volume>140</volume>:<fpage>1259</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">27788043</pub-id></mixed-citation>
              </ref>
              <ref id="bib24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pal</surname><given-names>SK</given-names></string-name>, <string-name><surname>McGregor</surname><given-names>B</given-names></string-name>, <string-name><surname>Suárez</surname><given-names>C</given-names></string-name>, <string-name><surname>Tsao</surname><given-names>C-K</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>W</given-names></string-name>, <string-name><surname>Vaishampayan</surname><given-names>U</given-names></string-name>, <etal/></person-group>. <article-title>Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study</article-title>. <source>J Clin Oncol</source><year>2021</year>;<volume>39</volume>:<fpage>3725</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">34491815</pub-id></mixed-citation>
              </ref>
              <ref id="bib25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDermott</surname><given-names>DF</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J-L</given-names></string-name>, <string-name><surname>Ziobro</surname><given-names>M</given-names></string-name>, <string-name><surname>Suarez</surname><given-names>C</given-names></string-name>, <string-name><surname>Langiewicz</surname><given-names>P</given-names></string-name>, <string-name><surname>Matveev</surname><given-names>VB</given-names></string-name>, <etal/></person-group>. <article-title>Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma</article-title>. <source>J Clin Oncol</source><year>2021</year>;<volume>39</volume>:<fpage>1029</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">33529058</pub-id></mixed-citation>
              </ref>
              <ref id="bib26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martínez Chanzá</surname><given-names>N</given-names></string-name>, <string-name><surname>Xie</surname><given-names>W</given-names></string-name>, <string-name><surname>Asim Bilen</surname><given-names>M</given-names></string-name>, <string-name><surname>Dzimitrowicz</surname><given-names>H</given-names></string-name>, <string-name><surname>Burkart</surname><given-names>J</given-names></string-name>, <string-name><surname>Geynisman</surname><given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study</article-title>. <source>Lancet Oncol</source><year>2019</year>;<volume>20</volume>:<fpage>581</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">30827746</pub-id></mixed-citation>
              </ref>
              <ref id="bib27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGregor</surname><given-names>B</given-names></string-name>, <string-name><surname>Mortazavi</surname><given-names>A</given-names></string-name>, <string-name><surname>Cordes</surname><given-names>L</given-names></string-name>, <string-name><surname>Salabao</surname><given-names>C</given-names></string-name>, <string-name><surname>Vandlik</surname><given-names>S</given-names></string-name>, <string-name><surname>Apolo</surname><given-names>AB</given-names></string-name>, <etal/></person-group>. <article-title>Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review</article-title>. <source>Cancer Treat Rev</source><year>2022</year>;<volume>103</volume>:<fpage>102333</fpage>.<pub-id pub-id-type="pmid">35033866</pub-id></mixed-citation>
              </ref>
              <ref id="bib28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Apolo</surname><given-names>AB</given-names></string-name>, <string-name><surname>Nadal</surname><given-names>R</given-names></string-name>, <string-name><surname>Girardi</surname><given-names>DM</given-names></string-name>, <string-name><surname>Niglio</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ley</surname><given-names>L</given-names></string-name>, <string-name><surname>Cordes</surname><given-names>LM</given-names></string-name>, <etal/></person-group>. <article-title>Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>3672</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">32915679</pub-id></mixed-citation>
              </ref>
              <ref id="bib29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDermott</surname><given-names>DF</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J-L</given-names></string-name>, <string-name><surname>Bjarnason</surname><given-names>GA</given-names></string-name>, <string-name><surname>Larkin</surname><given-names>JMG</given-names></string-name>, <string-name><surname>Gafanov</surname><given-names>RA</given-names></string-name>, <string-name><surname>Kochenderfer</surname><given-names>MD</given-names></string-name>, <etal/></person-group>. <article-title>Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma</article-title>. <source>J Clin Oncol</source><year>2021</year>;<volume>39</volume>:<fpage>1020</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">33529051</pub-id></mixed-citation>
              </ref>
              <ref id="bib30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reck</surname><given-names>M</given-names></string-name>, <string-name><surname>Rodríguez-Abreu</surname><given-names>D</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>AG</given-names></string-name>, <string-name><surname>Hui</surname><given-names>R</given-names></string-name>, <string-name><surname>Csőszi</surname><given-names>T</given-names></string-name>, <string-name><surname>Fülöp</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>375</volume>:<fpage>1823</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">27718847</pub-id></mixed-citation>
              </ref>
              <ref id="bib31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname><given-names>K</given-names></string-name>, <string-name><surname>Lein</surname><given-names>M</given-names></string-name>, <string-name><surname>Ringsdorf</surname><given-names>M</given-names></string-name>, <string-name><surname>Roigas</surname><given-names>J</given-names></string-name>, <string-name><surname>Schnorr</surname><given-names>D</given-names></string-name>, <string-name><surname>Loening</surname><given-names>SA</given-names></string-name>, <etal/></person-group>. <article-title>Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma</article-title>. <source>J Urol</source><year>2006</year>;<volume>176</volume>:<fpage>1326</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">16952623</pub-id></mixed-citation>
              </ref>
              <ref id="bib32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fohr</surname><given-names>B</given-names></string-name>, <string-name><surname>Dunstan</surname><given-names>CR</given-names></string-name>, <string-name><surname>Seibel</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Clinical review 165: Markers of bone remodeling in metastatic bone disease</article-title>. <source>J Clin Endocrinol Metab</source><year>2003</year>;<volume>88</volume>:<fpage>5059</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">14602728</pub-id></mixed-citation>
              </ref>
              <ref id="bib33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Albiges</surname><given-names>L</given-names></string-name>, <string-name><surname>Gurney</surname><given-names>HP</given-names></string-name>, <string-name><surname>Atduev</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)</article-title>. <source>Ann Oncol</source><year>2022</year>;<volume>33</volume>:<fpage>S660</fpage>–<lpage>80</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
